ArticleFrontiers in oncology2022

Clinical Benefit of Niraparib to TKI/mTORi-Resistance Metastatic ccRCC With

Bi-Jun Lian et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.